Artios raises $84M for developing cancer drugs targeting DNA repair pathway
The UK firm is developing drugs targeting DNA damage response, similar to approved PARP inhibitors for gynecologic cancers.
SV Health Investors rebranding reflects increased investment in health IT
The investment firm formerly known as SV Life Sciences has shifted its investment allocation for healthcare services/digital health companies from 25 percent to 40 percent.
presented by
Immune Support on Demand: Ranking the Top Mobile IV Therapy Companies
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.